LSL Pharma Group Cash Flow Statement

Financials in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-	-2.82	3.32	-8.47	-8.06
Depreciation & Amortization	2.88	2.53	1.51	1.13	1.05
Stock-Based Compensation	0.18	0.18	0.42	2.12	-
Other Adjustments	1.43	1.14	-2.91	2.9	0.88
Changes in Other Operating Activities	-4.31	-3.47	-3.99	-4.74	2.97
Operating Cash Flow	-5.5	-2.45	-1.65	-7.07	-3.16
Capital Expenditures	-1.89	-2.02	-3.12	-0.66	-1
Purchases of Intangible Assets	-3.27	-2.94	-1.08	-0.36	-
Payments for Business Acquisitions	-	-	-3.26	-	-
Other Investing Activities	-	-2.5	-	-	-
Investing Cash Flow	-7.66	-7.46	-7.46	-1.02	-1
Short-Term Debt Issued	4.05	-1.15	0.4	0.2	0.5
Net Short-Term Debt Issued (Repaid)	4.05	-1.15	0.4	0.2	0.5
Long-Term Debt Issued	21.07	21.67	8.72	4.05	3.46
Long-Term Debt Repaid	-7.98	-8.1	-5.92	-2.53	-0.82
Net Long-Term Debt Issued (Repaid)	13.09	13.57	2.8	1.52	2.64
Issuance of Common Stock	2.32	2.32	8.23	9.46	2.37
Net Common Stock Issued (Repurchased)	2.32	2.32	8.23	9.46	2.37
Other Financing Activities	-4.95	-4.58	-2.03	-3.09	-2.08
Financing Cash Flow	13.75	10.16	9.4	8.1	3.42
Net Cash Flow	0.59	0.25	0.29	0.01	-0.74
Free Cash Flow	-7.39	-4.46	-4.77	-7.73	-4.16
FCF Margin	-21.47%	-15.53%	-26.89%	-77.04%	-50.66%
Free Cash Flow Per Share	-0.04	-0.04	-0.05	-0.10	-0.06
Levered Free Cash Flow	8.33	6.64	0.91	-11.02	-1.9
Unlevered Free Cash Flow	-7.72	-5.04	-4.79	-6.27	-10.92